Citius Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Citius Pharmaceuticals Inc CTXR.OQ reported a quarterly adjusted loss of 80 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.50. The mean expectation of three analysts for the quarter was for a loss of 59 cents per share. Wall Street expected results to range from -80 cents to -21 cents per share.

• Reported revenue was zero​; analysts expected $4.32 million.

• Citius Pharmaceuticals Inc's reported EPS for the quarter was a loss of 80 cents​.

• The company reported a quarterly loss of $8.79 million.

• Citius Pharmaceuticals Inc shares had fallen by 21.4% this quarter and lost 68.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 10.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $5.00, about 75% above its last closing price of $1.25

This summary was machine generated from LSEG data August 12 at 08:53 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)